Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study developed a DPC cell line by introducing mutant CDK4, Cyclin D1, and TERT, making it a promising tool to study downstream signaling pathways activated by testosterone in androgenetic alopecia.

This case study reports that an infant with maple syrup urine disease developed acrodermatitis dysmetabolica due to low isoleucine levels, and increasing the isoleucine dose improved the condition.

The project developed and tested a method using plasma rich platelets to treat hair loss.

This study found that aminoguanidine induced increased VEGF mRNA expression in stored hair follicle micrografts, suggesting potential for developing growth-promoting storage solutions in hair restoration surgery.

This study developed the Alopecia Areata Patient Priority Outcome (AAPPO), a new tool designed to measure and capture the symptoms and impacts of alopecia areata that matter most to patients.

In this study, a newly designed protein degrader targeting androgen receptors showed promise in reversing hair regrowth inhibition in a mouse model of androgenetic alopecia, suggesting potential as a novel and safe treatment strategy.

In this study, researchers using Arabidopsis thaliana found that adenosine may inhibit root hair growth and stomatal opening, suggesting it plays a signaling role in plants similar to its function in animal cells, potentially revealing a new adenosine-like receptor pathway.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

This study found that 308 nm excimer lamp therapy provides a good clinical response with fewer adverse effects for limited alopecia areata but is less effective for widespread hair loss like alopecia totalis.

This article reviews characteristics and mental health impacts of alopecia areata but provides no new clinical findings; future research is encouraged.

IMG-007 helps regrow hair and reduce scalp inflammation in severe alopecia areata.

In this study, researchers developed a near-infrared-responsive nanoplatform that synergistically enhances chronic wound healing by accelerating mitochondrial restoration and immune modulation, leading to enhanced wound repair and high-quality healing in diabetic rat models.

This study found that apremilast treatment did not result in sustained improvement for most patients with treatment-resistant alopecia areata, although one patient experienced significant benefit.

This study of photobiomodulation therapy devices for androgenetic alopecia found variable improvements in hair grade across different skin types and devices, suggesting a need for larger, more comprehensive trials.

This study found that modifying adipose-derived stem cells to overexpress the adhesion protein JAM-A increased the adhesion and resilience of dermal papilla cells in the context of androgenic alopecia, potentially facilitating hair regrowth despite challenges such as damage from dihydrotestosterone and macrophages.

This review discusses the epidemiology, pathophysiology, diagnosis, and management of male androgenetic alopecia, noting that combination treatments, including FDA-approved and emerging therapies, may improve outcomes without added side effects.

This study found that full-length Agouti protein modulates melanocortin receptor signaling through a dual mechanism involving competitive antagonism and receptor down-regulation, whereas the carboxyl-terminal fragment acts solely as a competitive antagonist.

In this study, researchers developed a new topical atraric acid formulation, AA-TF#15, which showed a significantly higher drug penetration and increased hair regrowth in mice compared to minoxidil and finasteride treatments, suggesting its potential effectiveness for treating scalp androgenic alopecia.

In this study, the researchers identified that perturbing both AKT1 and MDM2 significantly reduces epithelial-mesenchymal transition in melanoma, proposing Cialis and Finasteride as potential therapeutic candidates with favorable properties for managing aggressive melanoma.

In this study, topical adenosine 0.75% and minoxidil 5% had similar recovery rates for androgenetic alopecia, but patients reported higher satisfaction with adenosine due to quicker hair loss prevention and new hair appearance.

This study found that a topical solution combining 0.25% finasteride with 3% minoxidil significantly improved hair growth, as measured by hair density, diameter, and global assessment, in men with androgenetic alopecia, compared to 3% minoxidil alone, over 24 weeks without systemic adverse effects reported.

This study found that a specific fragment of AIMP1 secreted by hair follicle stem cells can stimulate dermal papilla cells and promote hair regrowth.

Alpha-MSH affects mitochondrial function, and MC1R mutations may increase skin aging.

This study discusses zinc's vital role in skin cell growth and how its deficiency can lead to acrodermatitis enteropathica, marked by symptoms like alopecia and dermatitis. It notes that similar symptoms appear in people with certain metabolic conditions, referred to as acrodermatitis dysmetabolica.

This study identified that α-ketobutyrate (α-KB) extends lifespan and improves health markers in Caenorhabditis elegans and aged mice by modulating pyruvate metabolism and activating AMPK pathways, with potential implications for human anti-aging treatments.

In this study, researchers found that crude extracts from Avicennia marina and its component avicequinone C inhibit mechanisms contributing to androgenic alopecia in vitro, including 5α-reductase activity and DHT-AR interactions, potentially promoting hair growth and delaying the catagen phase in human dermal papilla cells.

This study found that Regenera ActivaAMT significantly improved hair growth and patient satisfaction in both men and women with Androgenetic Alopecia, suggesting it may be an effective alternative to hair transplants.